​As a highly fatal virus with no approved treatments sparks border screenings in Thailand and Nepal, our NiV IgG/IgM Rapid Test Device offers a critical first line of defense.

Following recent reports of Nipah virus (NiV) cases in India’s West Bengal state—a virus with a 40%–75% fatality rate​ and significant transmission risks—global health agencies have intensified screening efforts. Our NiV IgG/IgM Rapid Test Device, now in mass production, delivers results within 10 minutes, enabling swift identification of infections at homes, clinics, and borders. This product addresses the urgent need for accessible, rapid testing during a potential public health crisis.